Neurotech International Limited
On 12 September 2016 (“Prospectus Date”), Neurotech International Limited (ACN 610 205 402) (“Neurotech” or “the Company”) lodged a prospectus (“Prospectus”) with the Australian Securities and Investments Commission (“ASIC”) for the offer of 35,000,000 fully paid ordinary shares in the Company (“Shares”) at an issue price of 20 cents per Share to raise $7,000,000, and the offer of up to 2,529,076 options to acquire Shares to the Lead Manager (as those terms are defined in the Prospectus).
THE OFFER HAS NOW CLOSED, AND THE COMPANY IS NO LONGER ACCEPTING APPLICATIONS FOR SHARES.
An electronic copy of the Prospectus can be obtained in PDF format by clicking below after confirming agreement to the following.
This is an important document that should be read in its entirety. If you do not understand it, you should consult your professional adviser without delay. The paper form of the electronic Prospectus is accessible through this website has been lodged with ASIC.
Applications for securities referred to in the Prospectus must be made in accordance with the terms and conditions set out in the Prospectus. Applications for securities must be made on an application form that accompanies a complete hard copy of the Prospectus. There is no facility for online applications.
The Company will not issue any Shares on the basis of this Prospectus later than 13 months after the Prospectus Date.
The Prospectus does not constitute an offer in any place in which, or to any person to whom, it will not be lawful to make such an offer. No action has been taken to lodge, register or file the Prospectus in any jurisdiction outside Australia. The distribution of this Prospectus outside Australia may be restricted by law and persons who come into possession of this Prospectus outside Australia should seek advice on and observe any such restrictions. The investment described in this Prospectus has not been recommended by any regulatory authority of any jurisdiction including ASIC.
The information on this website is provided for information purposes only and is subject to change without notice. Nothing contained on this website or in the Prospectus constitutes investment, legal, accounting, business, tax or other advice. The information on this website and in the Prospectus does not take into account your investment objectives, financial situation or particular needs. The information on this website does not form part of the Prospectus.
By accessing the Prospectus, you are taken to have confirmed that you have read and understood the notice and agree to these terms and conditions.
The Board of Neurotech sets a high standard in fulfilling its obligations and responsibilities to stakeholders. As such the Board has established a set of corporate governance practices and procedures in order to carry out their fiduciary duties and obligations. These guidelines may be subject to modification as the Board deems appropriate in the best interests of Neurotech or as required by applicable laws and regulations.
Audit Committee CharterView Document (PDF)
Continuous Disclosure PolicyView Document (PDF)
Corporate Code of ConductView Document (PDF)
Diversity PolicyView Document (PDF)
Nomination Committee CharterView Document (PDF)
Remuneration Committee CharterView Document (PDF)
Risk Management PolicyView Document (PDF)
Securities Trading PolicyView Document (PDF)
Shareholder Communication PolicyView Document (PDF)